Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a note issued to investors on Monday. The firm set a “buy” rating on the biotechnology company’s stock.

ADAP has been the topic of several other reports. Scotiabank cut their price target on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a research note on Friday, March 21st. HC Wainwright reduced their target price on Adaptimmune Therapeutics from $3.50 to $3.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Wells Fargo & Company dropped their price target on Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a research note on Friday, March 21st. Finally, Guggenheim reduced their price objective on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a research note on Wednesday, March 26th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $1.83.

Adaptimmune Therapeutics Stock Up 3.4 %

Adaptimmune Therapeutics stock opened at $0.22 on Monday. Adaptimmune Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.48. The stock has a market cap of $57.18 million, a PE ratio of -1.01 and a beta of 2.84. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The stock’s fifty day moving average is $0.42 and its two-hundred day moving average is $0.60.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The business had revenue of $3.22 million during the quarter, compared to analyst estimates of $16.56 million. On average, sell-side analysts expect that Adaptimmune Therapeutics will post -0.14 EPS for the current fiscal year.

Institutional Trading of Adaptimmune Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. increased its holdings in shares of Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 28,526 shares during the period. Two Sigma Advisers LP increased its stake in Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 58,787 shares during the period. Two Sigma Investments LP raised its position in Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after buying an additional 19,146 shares during the last quarter. Virtu Financial LLC boosted its holdings in shares of Adaptimmune Therapeutics by 21.5% in the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 21,688 shares in the last quarter. Finally, LPL Financial LLC increased its stake in shares of Adaptimmune Therapeutics by 106.5% during the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 94,623 shares during the period. 31.37% of the stock is owned by hedge funds and other institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.